Get the Stockscreener App
698.74
0.57%
-4.04
After Hours:
698.75
0.010
+0.00%
Regeneron Pharmaceuticals Inc stock is traded at $698.74, with a volume of 989.34K.
It is down -0.57% in the last 24 hours and up +3.83% over the past month.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$702.78
Open:
$701.32
24h Volume:
989.34K
Relative Volume:
1.18
Market Cap:
$76.39B
Revenue:
$14.20B
Net Income/Loss:
$4.41B
P/E Ratio:
18.25
EPS:
38.28
Net Cash Flow:
$3.54B
1W Performance:
-0.23%
1M Performance:
+3.83%
6M Performance:
-41.02%
1Y Performance:
-27.67%
1-Day Range:
$693.71
$708.58
1-Week Range:
$693.71
$739.00
52-Week Range:
$642.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman - GlobeNewswire Inc.
REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Bellecapital International Ltd. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
John G Ullman & Associates Inc. Invests $2.36 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Flputnam Investment Management Co. Sells 12,619 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mutual of America Capital Management LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sterling Investment Advisors Ltd. Buys 715 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Birinyi Associates Inc. Invests $1.48 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amalgamated Bank Sells 2,447 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Mn Services Vermogensbeheer B.V. - MarketBeat
Illumine Investment Management LLC Invests $2.13 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
10,847 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Anchor Capital Advisors LLC - MarketBeat
FourThought Financial Partners LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bank of New York Mellon Corp - MarketBeat
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Drug Kickback Ruling Will Make FCA Liability Harder To Prove - Law360
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Says Linvoseltamab Recommended for EU Approval to Treat Multiple Myeloma - Marketscreener.com
EMA backs Regeneron’s linvoseltamab for multiple myeloma - Investing.com
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma - TradingView
Regeneron's Multiple Myeloma Drug Clears Critical EU Regulatory HurdleWhat's Next? - StockTitan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by QRG Capital Management Inc. - MarketBeat
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Reduced by Trifecta Capital Advisors LLC - MarketBeat
Shareholders that lost money on Regeneron Pharmaceuticals, - GlobeNewswire
2025-02-27 | Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)March 10, 2025 Deadline to JoinContact Levi & Korsinsky | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Pharmaceuticals (NasdaqGS:REGN) BLA Resubmission For Odronextamab In R/R FL Accepted By FDA - Simply Wall St
Regeneron’s Gene Therapy DB-OTO Improves Hearing in Children With Otoferlin-Related Hearing Loss - CGTLive™
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - PR Newswire
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’ - BioSpace
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Proficio Capital Partners LLC Has $156.28 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-27 | Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron: Is It the Perfect Biotech Stock for Value and Growth? - MarketBeat
Oppenheimer & Co. Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron makes second bid for blood cancer therapy approval - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by NewEdge Wealth LLC - MarketBeat
Apriem Advisors Sells 1,033 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class ActionREGN - PR Newswire
National Pension Service Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sigma Planning Corp Has $557,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab - TipRanks
Seasonal Allergic Rhinitis Treatment Market Size in the 7MM - openPR
Allergic Rhinitis Therapeutic Market Size in the 7MM was ~USD - openPR
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join - GlobeNewswire
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REGN DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors ... - The Bakersfield Californian
REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc. - TipRanks
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma - The Manila Times
FDA reviews Regeneron's lymphoma drug application - Investing.com
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.00%
4.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):